Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Paladin Labs gets rights to Immuron's Travelan and option to IMM255

07 Dec 2011

Executive Summary

Australian biotech Immuron Ltd. (developing dairy-derived antibody therapeutics) has licensed Canadian specialty pharmaco Paladin Labs Inc. exclusive rights to market and sell the over-the-counter traveler’s diarrhea drug Travelan in Canada, Latin America, Argentina, Brazil, Columbia, Mexico, sub-Saharan Africa, and South Africa. Paladin also has the option to acquire rights to Immuron's preclinical influenza candidate IMM255 in the same territories.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • OTC, Consumer
    • Specialty Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
Deal Status
  • Final
Deal Type
  • Alliance
    • Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By